Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
  • A61K8/0241—Containing particulates characterized by their shape and/or structure
  • A61K8/0245—Specific shapes or structures not provided for by any of the groups of A61K8/0241
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
  • A61K8/04—Dispersions; Emulsions
  • A61K8/06—Emulsions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
  • A61K8/04—Dispersions; Emulsions
  • A61K8/06—Emulsions
  • A61K8/064—Water-in-oil emulsions, e.g. Water-in-silicone emulsions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
  • A61K8/25—Silicon; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
  • A61K8/27—Zinc; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
  • A61K8/41—Amines
  • A61K8/416—Quaternary ammonium compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
  • A61K8/585—Organosilicon compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
  • A61K8/73—Polysaccharides
  • A61K8/738—Cyclodextrins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
  • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
  • A61K8/89—Polysiloxanes
  • A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
  • A61K8/894—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone modified by a polyoxyalkylene group, e.g. cetyl dimethicone copolyol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
  • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Definitions

• the present invention relates to water-in-oil type emulsion sunscreen cosmetics.
• the present invention relates to water-in-oil type emulsion sunscreen cosmetics that have an excellent UV protection capability and have excellent effects in the prevention and inhibition of discoloration (discoloration to red).
• UV absorbers or UV scattering agents are blended in sunscreen cosmetics (refer to patent literatures 1 and 2, for example).
• Octocrylene is an all-purpose UV absorber.
• a hydrophobized UV scattering agent especially zinc oxide
• a cationic surfactant in water-in-oil type sunscreen cosmetics.
• Patent Literature 1 Japanese Unexamined Patent Publication No. H10-120543 (paragraph numbers [0032], [0041], [0045], etc.)
• Patent Literature 2 PCT Japanese Translation Patent Publication No. 2002-521417 (claim section etc.)
• the object of the present invention is to provide water-in-oil type emulsion sunscreen cosmetics that solve the above-described problem, achieve an excellent UV blocking effect, and have excellent effects in the prevention and inhibition of discoloration (discoloration to red).
• the present inventors have diligently studied to solve the above-described problem. As a result, the present inventors have found that an excellent UV blocking effect and the prevention and inhibition effects of red discoloration could be achieved by blending silica into a system where octocrylene, a hydrophobized UV scattering agent (especially zinc oxide), and a cationic surfactant are blended, thus leading to completion of the present invention.
• the present invention provides water-in-oil type emulsion sunscreen cosmetics comprising: (a) octocrylene; (b) hydrophobized zinc oxide; (c) cationic surfactant; and (d) silica.
• the present invention provides the above-described water-in-oil type emulsion sunscreen cosmetics comprising said component (c), with which component (b) is surface-coated.
• the present invention provides the above-described water-in-oil type emulsion sunscreen cosmetics wherein the blending amount of said component (a) is 0.2 to 15% by mass.
• the present invention provides the above-described water-in-oil type emulsion sunscreen cosmetics wherein the blending amount of said component (b) is 0.2 to 30% by mass.
• the present invention provides the above-described water-in-oil type emulsion sunscreen cosmetics further comprising: (e) 0.01 to 20% by mass of silicone surfactant.
• water-in-oil type emulsion sunscreen cosmetics that can satisfactorily achieve an excellent UV blocking effect and have excellent effects in the prevention and inhibition of discoloration (discoloration to red) can be provided.
• Octocrylene (another name: 2-cyano-3,3-diphenyl-2-propenoic acid 2-ethylhexyl ester), which is component (a) used in the present invention, is a UV protection agent, and it is a publicly known material.
• Octocrylene can normally be prepared by the esterification reaction of cyanoacetic acid and 2-ethylhexanol in a solvent (for example, cyclohexane) to 2-ethylhexyl cyanoacetate and by the subsequent condensation reaction of the obtained 2-ethylhexyl cyanoacetate with benzophenone.
• octocrylene may be produced in a state that 2-ethylhexyl cyanoacetate is not completely used in the condensation process and 2-ethylhexyl cyanoacetate is partially left.
• concentration is preferably 400 ppm or lower, more preferably 200 ppm or lower, and further more preferably 100 ppm or lower.
• concentration of 2-ethylhexyl cyanoacetate is zero.
• Component (a) includes, for example, commercial products such as “Uvinul N539” (BASF) or “Parsol 340” (DSM Nutrition Japan K.K.), and they can be used desirably.
• the blending amount of component (a) is 0.2 to 15% by mass with respect to the cosmetics of the present invention, preferably 0.5 to 10% by mass, and more preferably 1 to 7% by mass. If the blending amount is less than 0.2% by mass, a satisfactory UV protection capability cannot be achieved. On the other hand, if the blending amount exceeds 15% by mass, a high tendency of discoloration (discoloration to red) is observed and there is a concern with usability deterioration such as stickiness and an oily feeling.
• Hydrophobized zinc oxide which is used as component (b), is a UV scattering agent, and it can effectively be dispersed in the oil phase (outer phase) after hydrophobizing treatment.
• zinc oxide is preferably prepared into fine particles.
• the average primary particle size of zinc oxide fine particles can be about 1 to 50 nm. However, the size is not limited to this size.
• hydrophobizing treatment is not limited in particular, and a publicly known method can be used for treatment.
• hydrophobized zinc oxide examples include metallic soap-treated zinc oxide, for example by aluminum stearate; fatty acid-dextrin treated zinc oxide, for example by cyclodextrin-fatty acid ester; amino acid treated zinc oxide; oily polysiloxane treated zinc oxide, for example by methylhydrogenpolysiloxane, methylhydrogenpolysiloxane/dimethylpolysiloxane copolymer, methicone, or dimethicone; fluorine-treated zinc oxide, for example by perfluoroalkyl phosphate; and silane coupling agent treated zinc oxide, for example by octyltriethoxysilane.
• the blending amount of component (b) is 0.2 to 30% by mass with respect to the cosmetics of the present invention, preferably 1 to 25% by mass, and more preferably 10.1 to 25% by mass. If the blending amount is less than 0.2% by mass, a satisfactory UV protective effect cannot be achieved. On the other hand, if the blending amount exceeds 30% by mass, there is a concern with the discoloration (discoloration to red) and usability deterioration as typified by smoothlessness.
• the cationic surfactant which is component (c), is not limited in particular so far as the cationic surfactant can be generally used in cosmetics.
• examples include stearyltrimethylammonium chloride, hexadecyltrimethylammonium chloride, tetradecyltrimethylammonium chloride, lauryltrimethylammonium chloride, C12 monohydroxyalkylether cation, dihydroxyalkylether cation, dihydroxyalkylether cation, cocodiamidopropyl cation, cocodicarboxyethyl cation, C16 dicarboxyethyl cation, C18 dicarboxyethyl cation, POP(15) diethylmethyl cation, POP(25) diethylmethyl cation, POP(40) diethylmethyl cation, C12 diamidopropylmethylamine, C14 diamidopropylmethylamine, C16 diamidopropy
• the especially desirable component (c) is distearyldimethylammonium salt, dihexadecyldimethylammonium salt, ditetradecyldimethylammonium salt, didodecyldimethylammonium salt, stearyltrimethylammonium chloride, hexadecyltrimethylammonium chloride, tetradecyltrimethylammonium chloride, or dodecyltrimethylammonium chloride.
• One or more of component (c) can be used.
• Silica which is component (d), is silicon dioxide (silicic anhydride).
• Treated silicas such as dimethylsilanized silicic anhydride and trimethylsilanized silicic anhydride can also be used.
• the silica can be of any shape; the shape can be spherical and porous, plate-like and nonporous, particulate, rod-like and porous, or spherical and nonporous, and there is no particular restriction. However, spherical porous silica, particulate silica, or rod-like porous silica is preferably used.
• Component (d) includes, for example, commercial products such as “Sunsphere L-51” (manufactured by Asahi Glass Co., Ltd.), “Chemiselen” (manufactured by Sumitomo Chemical Co., Ltd.), “Aerosil 200” (manufactured by Nippon Aerosil Co., Ltd.), “Spherical Silica P1500” (manufactured by Catalysts & Chemicals Ind. Co., Ltd.), and “Mesoporous Silica”, and these can be used desirably.
• Commercial products such as “Sunsphere L-51” (manufactured by Asahi Glass Co., Ltd.), “Chemiselen” (manufactured by Sumitomo Chemical Co., Ltd.), “Aerosil 200” (manufactured by Nippon Aerosil Co., Ltd.), “Spherical Silica P1500” (manufactured by Cataly
• component (b), component (c), and component (d) are not limited in particular. Examples include:
• Blending mode in which component (b), component (c), and component (d) are individually blended.
• Blending mode in which the hydrophobized and cation-treated zinc oxide, which is obtained by treating component (b) with component (c), is blended with component (d).
• Blending mode in which the hydrophobized, cation-treated, and silica-coated zinc oxide, which is obtained by coating, with component (d), the hydrophobized and cation-treated zinc oxide obtained by treating component (b) with component (c), is blended.
• Blending mode in which the hydrophobized silica-coated zinc oxide, which is obtained by treating component (b) with component (d), is blended with component (c).
• Blending mode in which untreated zinc oxide is silica-coated with component (d), and this silica-coated zinc oxide is hydrophobized with a hydrophobizing agent and cation-treated with component (c).
• the blending mode is not limited by the above-described examples.
• the blending of component (d) may be achieved by silica-coated powders obtained by coating the surface of powders, except for component (b), with silica.
• component (c) and component (d) are as follows.
• the blending amount of component (c) in cosmetics is preferably 0.0001 to 10% by mass and more preferably 0.001 to 1% by mass.
• the blending amount of component (c) is preferably 0.5 to 10% by mass with respect to zinc oxide (base body). If the blending amount of component (c) is too small, the formulation stability, removability, and the powder dispersibility tend to be become lower. On the other hand, if the blending amount of component (c) is too large, the discoloration may not be inhibited even by blending component (d).
• the blending amount of component (d) in cosmetics is preferably 0.1 to 20% by mass and more preferably 0.5 to 10% by mass.
• the blending amount of component (d) is preferably 0.1 to 20% by mass with respect to zinc oxide (base body). If the blending amount of component (d) is too small, the dispersion stability tends to become lower. On the other hand, if the blending amount of component (d) is too large, the UV protection capability tends to become lower.
• component (d) and component (c) are individually blended, it is desirable to blend component (d) in a mass ratio of 0.01:6 or higher with respect to component (c). In this case, if the blending amount of component (d) is too small, the discoloration to red may take place.
• the production can also be achieved by treating a commercial hydrophobized powder with a cationic surfactant.
• the amounts of coating of a hydrophobizing agent and a cationic surfactant are preferably in the mass ratio of 1:1 to 9:1. If the rate of the cationic surfactant is larger than the above-described range, the water resistance may become poor. If the rate is smaller, the dispersibility and removability may become poor.
• a (e) silicone surfactant is further blended as an emulsifying agent.
• the silicone surfactant is not limited in particular so far as it is usable in water-in-oil emulsion systems. Examples include poly(oxyethylene/oxypropylene) methylpolysiloxane copolymer, polyoxyethylene methylpolysiloxane copolymer, silicone-chain branched-type methylpolysiloxane copolymer, alkyl-chain branched-type polyoxyethylene methylpolysiloxane copolymer, alkyl-chain/silicone-chain branched-type polyoxyethylene methylpolysiloxane copolymer, crosslinked-type polyoxyethylene methylpolysiloxane, alkyl-containing crosslinked-type polyoxyethylene methylpolysiloxane, branched-type polyglycerin-modified silicone, crosslinked-type polyglycerin-modified silicone, alky
• Examples of the above-described poly(oxyethylene/oxypropylene)methylpolysiloxane copolymers include PEG/PPG-20/22 butyl ether dimethicone (“KF-6012”, manufactured by Shin-Etsu Chemical Co., Ltd.), PEG/PPG-20/20 dimethicone (“BY22-008M”, manufactured by Toray Dow Corning Silicone Co., Ltd.), lauryl PEG/PPG-18 methicone (“5200 Formulation Aid”, manufactured by Dow Corning Toray Co., Ltd.), PEG/PPG-19/19 dimethicone (“5330 Fluid”, manufactured by Dow Corning Toray Co., Ltd.), and PEG/PPG-15/15 dimethicone (“5330 Fluid”, manufactured by Dow Corning Toray Co., Ltd.).
• polyoxyethylene methylpolysiloxane copolymers examples include PEG-11 methyl ether dimethicone (“KF-6011”, manufactured by Shin-Etsu Chemical Co., Ltd.), PEG-9 dimethicone (“KF-6013”, manufactured by Shin-Etsu Chemical Co., Ltd.), PEG-3 dimethicone (“KF-6015”, manufactured by Shin-Etsu Chemical Co., Ltd.), PEG-9 methyl ether dimethicone (“KF-6016”, manufactured by Shin-Etsu Chemical Co., Ltd.), PEG-10 dimethicone (“KF-6017”, manufactured by manufactured by Shin-Etsu Chemical Co., Ltd.), PEG-11 methyl ether dimethicone (“KF-6018”, manufactured by Shin-Etsu Chemical Co., Ltd.), PEG-9 dimethicone (“KF-6019”, manufactured by Shin-Etsu Chemical Co., Ltd.), and PEG-12 dimethicone (“SH3771M”, “SH3772
• silicone-chain branched-type methylpolysiloxane copolymers examples include PEG-9 polydimethylsiloxyethyl dimethicone (“KF-6028”, manufactured by Shin-Etsu Chemical Co., Ltd.).
• alkyl-chain branched-type polyoxyethylene methylpolysiloxane copolymers examples include PEG/PPG-10/3 oleyl ether dimethicone (“KF-6026”, manufactured by Shin-Etsu Chemical Co., Ltd.).
• alkyl-chain/silicone-chain branched-type polyoxyethylene methylpolysiloxane copolymers examples include lauryl PEG-9 polydimethylsiloxyethyl dimethicone (“KF-6038”, manufactured by Shin-Etsu Chemical Co., Ltd.).
• crosslinked-type polyoxyethylene methylpolysiloxanes examples include dimethicone/(PEG-10/15) crosspolymer (“KSG-210”, manufactured by Shin-Etsu Chemical Co., Ltd.) and cyclomethicone/(PEG-12 dimethicone) crosspolymer (“9011 Silicone Elastomer Blend”, manufactured by Toray Dow Corning Silicone Co., Ltd.).
• alkyl-containing crosslinked-type polyoxyethylene methylpolysiloxanes examples include mineral oil/PEG-15 lauryl dimethicone crosspolymer (“KSG-310”, manufactured by Shin-Etsu Chemical Co., Ltd.), isododecane/PEG-15 lauryl dimethicone crosspolymer (“KSG-320”, manufactured by Shin-Etsu Chemical Co., Ltd.), trioctanoin/PEG-15 lauryl dimethicone crosspolymer (“KSG-330”, manufactured by Shin-Etsu Chemical Co., Ltd.), and squalane/PEG-15 lauryl dimethicone crosspolymer/PEG-10 lauryl dimethicone crosspolymer (“KSG-340”, manufactured by Shin-Etsu Chemical Co., Ltd.).
• KSG-310 mineral oil/PEG-15 lauryl dimethicone crosspolymer
• KSG-320 isododecane/PEG-15 lauryl dimethi
• branched-type polyglycerin-modified silicones examples include polyglyceryl-3 disiloxane dimethicone (“KF-6100”, manufactured by Shin-Etsu Chemical Co., Ltd.) and polyglyceryl-3 polydimethylsiloxyethyl dimethicone (“KF-6104”, manufactured by Shin-Etsu Chemical Co., Ltd.).
• crosslinked-type polyglycerin-modified silicones examples include dimethicone/(dimethicone/polyglycerin-3) crosspolymer (“KSG-710”, manufactured by Shin-Etsu Chemical Co., Ltd.).
• alkyl-containing crosslinked-type polyglycerin-modified silicones include mineral oil/(lauryl dimethicone/polyglycerin-3) crosspolymer (“KSG-810”, manufactured by Shin-Etsu Chemical Co., Ltd.), isododecane/(lauryl dimethicone/polyglycerin-3) crosspolymer (“KSG-820, manufactured by Shin-Etsu Chemical Co., Ltd.”), trioctanoin/(lauryl dimethicone/polyglycerin-3) crosspolymer (“KSG-830”, manufactured by Shin-Etsu Chemical Co., Ltd.), and squalane/(lauryl dimethicone/polyglycerin-3) crosspolymer (“KSG-840”, manufactured by Shin-Etsu Chemical Co., Ltd.).
• alkyl group branched-type polyglycerin-modified silicones examples include lauryl polyglyceryl-3 polydimethylsiloxyethyl dimethicone (“KF-6105”, manufactured by Shin-Etsu Chemical Co., Ltd.).
• polyoxyethylene methylpolysiloxane copolymer poly(oxyethylene/oxypropylene) methylpolysiloxane copolymer, silicone-chain branched-type methylpolysiloxane copolymer, and alkyl-chain/silicone-chain branched-type polyoxyethylene methylpolysiloxane copolymer are desirably used.
• the blending amount of component (e) in the sunscreen cosmetics of the present invention is preferably 0.01% by mass at the lower limit, more preferably 0.1% by mass or higher, and further more preferably 0.5% by mass or higher.
• the upper limit is preferably 20% by mass or lower and more preferably 10% by mass or lower. If the blending amount is less than 0.01% by mass, the stability of cosmetics tends to become poorer. On the other hand, if the blending amount largely exceeds 20% by mass, a sticky feeling is generated and the feeling in use tends to become poorer.
• the oil phase (outer phase) is 40 to 80% by mass and the water phase (inner phase) is 20 to 60% by mass.
• the cosmetics of the present invention in addition to the above-described components, other components normally be used in cosmetics can be blended as necessary so far as the objectives and effects of the present invention are not undermined.
• these components include water-soluble polymers, oil-soluble polymers, polymer powders, emulsifying agents (other than the above-described component (e)), waxes, alcohols, liquid fats, ester oils, hydrocarbon oils, silicone oils, fatty acids, higher alcohols, fatty acid esters, drugs, UV absorbers (other than the above-described component (a)), UV scattering agents (other than the above-described component (b)), and organic-modified clay minerals.
• the components are not limited by these examples.
• water-soluble polymers examples include a homopolymer and copolymers of 2-acrylamido-2-methyl propane sulfonic acid (hereinafter abbreviated as “AMPS”).
• the copolymer comprises comonomers such as vinylpyrrolidone, acrylamide, sodium acrylate, and hydroxyethyl acrylate.
• Examples include AMPS homopolymer, vinylpyrrolidone/AMPS copolymer, dimethylacrylamide/AMPS copolymer, acrylamide/AMPS copolymer, and sodium acrylate/AMPS copolymer.
• Further examples include carboxyvinyl polymer, ammonium polyacrylate, sodium polyacrylate, sodium acrylate/alkyl acrylate/sodium methacrylate/alkyl methacrylate copolymer, carrageenan, pectin, mannan, curdlan, chondroitin sulfate, starch, glycogen, gum arabic, sodium hyaluronate, tragacanth gum, xanthan gum, mucoitin sulfate, hydroxyethyl guar gum, carboxymethyl guar gum, guar gum, dextran, kerato sulfate, locust bean gum, succinoglucan, chitin, chitosan, carboxymethyl chitin, and agar.
• oil-soluble polymers examples include trimethylsiloxysilicate, alkyl-modified silicone, and polyamide-modified silicone.
• polymer powders examples include dimethicone crosspolymer, (dimethicone/vinyldimethicone) crosspolymer, polymethylsilsesquioxane, polyethylene, and polymethylmethacrylate.
• waxes examples include beeswax, candelilla wax, carnauba wax, lanolin, lanolin oil, and jojoba wax.
• emulsifying agents include glycerin fatty acid ester, polyglycerin fatty acid ester, polyoxyethylene glycerin fatty acid ester, sorbitan fatty acid ester, and polyoxyethylene sorbitan fatty acid ester.
• alcohols examples include lower alcohols such as ethanol and isopropanol; higher alcohols such as isostearyl alcohol, octyldodecanol, and hexyldecanol; and polyhydric alcohols such as ethylene glycol, propylene glycol, 1,3-butylene glycol, dipropylene glycol, and polybutylene glycol.
• liquid fats examples include avocado oil, camellia oil, turtle oil, macadamia nut oil, corn oil, mink oil, olive oil, rapeseed oil, egg oil, sesame oil, persic oil, wheat germ oil, sasanqua oil, castor oil, linseed oil, safflower oil, cottonseed oil, perilla oil, soybean oil, peanut oil, tea seed oil, kaya oil, rice bran oil, paulownia oil, Japanese tung oil, jojoba oil, germ oil, and triglycerin.
• avocado oil camellia oil, turtle oil, macadamia nut oil, corn oil, mink oil, olive oil, rapeseed oil, egg oil, sesame oil, persic oil, wheat germ oil, sasanqua oil, castor oil, linseed oil, safflower oil, cottonseed oil, perilla oil, soybean oil, peanut oil, tea seed oil, kaya oil, rice bran oil, pa
• ester oils include isopropyl myristate, cetyl octanoate, octyldodecyl myristate, isopropyl palmitate, butyl stearate, hexyl laurate, myristyl myristate, decyl oleate, hexyldecyl dimethyloctanoate, cetyl lactate, myristyl lactate, acetylated lanolin, isocetyl stearate, isocetyl isostearate, isononyl isononate, cholesteryl 12-hydroxystearate, ethylene glycol di-2-ethylhexanoate, dipentaerythritol fatty acid ester, N-alkylglycol monoisostearate, neopentyl glycol dicaprylate, diisostearyl malate, glyceryl di-2-heptylundecano
• hydrocarbon oils examples include liquid paraffin, ozokerite, squalane, pristane, paraffin, ceresin, squalene, petrolatum, microcrystalline wax, polyethylene wax, and Fischer-Tropsch wax.
• silicon oils examples include dimethylpolysiloxane, octamethylsiloxane, decamethyltetrasiloxane, methylhydrogenpolysiloxane, methylphenylpolysiloxane, hexamethylcyclotrisiloxane, octamethylcyciotetrasiloxane, and decamethylcyclopentasiloxane.
• fatty acids examples include lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, and arachidonic acid.
• higher alcohols examples include lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, behenyl alcohol, arachyl alcohol, batyl alcohol, chimyl alcohol, carnaubyl alcohol, ceryl alcohol, koryanyl alcohol, myricyl alcohol, lacceryl alcohol, elaidyl alcohol, isostearyl glyceryl ether, octyl alcohol, triacontyl alcohol, cerakyl alcohol, cetostearyl alcohol, oleyl alcohol, lanolin alcohol, hydrogenated lanolin alcohol, hexyldecanol, and octyldecanol.
• fatty acid esters examples include myristyl myristate, cetyl palmitate, cholesteryl stearate, and 2-octyldodecyl beeswax fatty acid.
• drugs examples include L-ascorbic acid and its salt derivatives, glycyrrhizic acid and its derivatives such as dipotassium glycyrrhizate and monoammonium glycyrrhizate, glycyrrhetinic acid and its derivatives such as stearyl glycyrrhetinate, allantoin, tranexamic acid and its salt derivatives, alkoxysalicylic acid and its salt derivatives, glutathione and its salt derivatives, allantoin, and azulene.
• L-ascorbic acid and its salt derivatives examples include L-ascorbic acid and its salt derivatives, glycyrrhizic acid and its derivatives such as dipotassium glycyrrhizate and monoammonium glycyrrhizate, glycyrrhetinic acid and its derivatives such as stearyl glycyrrhetinate, all
• UV absorbers include cinnamic acid derivatives such as ethylhexyl methoxycinnamate, isopropyl methoxycinnamate, and isoamyl methoxycinnamate; PABA derivatives such as para-aminobenzoic acid (hereinafter abbreviated as “PABA”), ethyl PABA, ethyl dihydroxypropyl PABA, ethylhexyl dimethyl PABA, and glyceryl PABA; salicylic acid derivatives such as homosalate, ethylhexyl salicylate, dipropylene glycol salicylate, and TEA salicylate; benzophenone derivatives such as benzophenone-1, benzophenone-2, benzophenone-3 or oxybenzone, benzophenone-4, benzophenone-5, benzophenone-6, benzophenone-8, benzophenone-9, and benzo
• UV scattering agents include hydrophobized inorganic pigments such as titanium dioxide, kaolin, and calcium carbonate.
• organic-modified clay minerals include quaternary ammonium cation modified clay minerals.
• the water-in-oil type emulsion sunscreen cosmetics of the present invention include products such as emulsion type and cream type. These products can be prepared by the conventional method by mixing the above-described essential components and the components that are normally blended in cosmetics.
• octocrylene ( * 1) , in which the amount of 2-ethylhexyl cyanoacetate is about 1000 ppm, and “octocrylene” ( * 2) , in which the amount of 2-ethylhexyl cyanoacetate is about 100 ppm, were used. They were the same in examples in Table 2 and examples in tables below Table 2.
• component (b) and component (d) in “(7) hydrophobized (silane treatment)/silica-coated zinc oxide [component (b)+component (d)]” were about 80% by mass and about 20% by mass, respectively.
• the percentage (mass ratio) of component (d) in “(8) hydrophobized (silane treatment)/silica-coated titanium dioxide [component (d)]” was about 10% by mass. That is, the blending amount of component (d) in sample I was 1.5% by mass.
• sample A (control) containing component (a) but not containing components (b) and (c) did not discolor to red even without blending component (d).
• Sample B containing components (a) and (b) but not containing component (c) did not discolor to red even without component (d).
• Samples C to E containing components (a) to (c) but not containing component (d) discolored to red.
• samples I and J in which component (d) was added by coating the powder therewith, did not discolor to red.
• Water-in-oil type emulsion sunscreen cosmetics of the compositions shown in Tables 6 and 7 were prepared according to the normal method. The prevention and inhibition effects of discoloration were evaluated for these samples according to the above-described evaluation criteria. The results are shown in Tables 6 and 7.
• component (b) and component (d) in “(17) hydrophobized (silane treatment)/silica-coated zinc oxide [component (b)+component (d)]” were about 80% by mass and about 20% by mass, respectively.
• the percentage (mass ratio) of component (d) in “(18) hydrophobized (silane treatment)/titanium dioxide [component (d)]” was about 10% by mass. That is, the blending amount of component (d) contained in sample 7, shown in Table 7, was 1.5% by mass, and the blending amount of component (d) contained in sample 11 was 0.5% by mass.
• Components (1) to (9) were mixed and dissolved at room temperature to prepare an oil phase in advance. Subsequently, components (10) to (13) were added, and the mixture was dispersively mixed with a disper. Components (14) to (16) were mixed, dissolved, and gradually added to the oil phase by stirring with a disper.
• the desired sunscreen milky lotion was obtained by mixing and dissolving to a sufficiently homogeneous state.
• Components (1) to (8) were mixed and dissolved at room temperature to prepare an oil phase in advance. Subsequently, components (9) to (12) were added, and the mixture was dispersively mixed with a disper. Components (13) to (15) were mixed, dissolved, and gradually added to the oil phase by stirring with a disper.
• the desired sunscreen milky lotion was obtained by mixing and dissolving to a sufficiently homogeneous state.
• Components (1) to (9) were mixed and dissolved at 70° C. to prepare an oil phase in advance. Subsequently, components (10) to (13) were added, and the mixture was dispersively mixed with a disper. Components (14) to (16) were mixed, dissolved, and gradually added to the oil phase by stirring with a disper. The desired sunscreen cream was obtained by mixing and dissolving to a sufficiently homogeneous state.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Birds (AREA)
• Epidemiology (AREA)
• Chemical & Material Sciences (AREA)
• Inorganic Chemistry (AREA)
• Dispersion Chemistry (AREA)
• Dermatology (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Physics & Mathematics (AREA)
• Geometry (AREA)
• Cosmetics (AREA)

Applications Claiming Priority (3)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=38437344

Family Applications (2)

Family Applications After (1)

Country Status (7)

Cited By (8)

Families Citing this family (6)

Citations (12)

Family Cites Families (10)

• 2007
  • 2007-02-20 KR KR1020087019364A patent/KR101371808B1/ko active IP Right Grant
  • 2007-02-20 EP EP07737302.5A patent/EP1990042B1/fr active Active
  • 2007-02-20 ES ES07737302.5T patent/ES2524777T3/es active Active
  • 2007-02-20 US US12/279,762 patent/US20100233103A1/en not_active Abandoned
  • 2007-02-20 WO PCT/JP2007/053043 patent/WO2007097304A1/fr active Application Filing
  • 2007-02-20 CN CN2007800059412A patent/CN101384245B/zh active Active
  • 2007-02-26 TW TW096106358A patent/TWI381853B/zh not_active IP Right Cessation
• 2014
  • 2014-03-03 US US14/195,647 patent/US9084724B2/en active Active

Patent Citations (12)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events